Medytox and Daewoong Pharmaceutical US ITC Final Ruling Postponed to December 16 (Update)

[Image source=Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] The U.S. International Trade Commission (ITC) has decided to postpone the final ruling on the botulinum strain dispute between Daewoong Pharmaceutical and Medytox to December 16 (local time). This is the second time the ITC has delayed the final ruling on this lawsuit.

According to the pharmaceutical industry on the 20th, the ITC postponed the final ruling on the lawsuit in which Medytox officially sued Daewoong Pharmaceutical for trade secret infringement from the previous day (local time) to the 16th of next month.

The ITC has not yet disclosed the reason for the delay. The industry views this as a schedule adjustment due to the local spread of the novel coronavirus (COVID-19).

[Image source=Yonhap News]

Originally, the ITC was scheduled to issue the final ruling on the lawsuit in which Medytox officially sued Daewoong Pharmaceutical for trade secret infringement on the 6th of this month, but on the 23rd of last month, it suddenly postponed it to the 19th of this month.

Since 2016, Medytox and Daewoong Pharmaceutical have been in conflict over the source of the botulinum strain, the raw material for botulinum toxin preparations commonly called 'Botox.' Medytox has claimed that Daewoong Pharmaceutical stole its botulinum strain, while Daewoong Pharmaceutical has firmly denied this, stating it is a different strain.

In a preliminary ruling last July, the ITC sided with Medytox, but the final ruling remains unpredictable. In the preliminary ruling, the ITC judged that Daewoong Pharmaceutical had stolen Medytox's botulinum strain and other trade secrets, but later accepted Daewoong Pharmaceutical's objection and decided to reexamine the case.

This content was produced with the assistance of AI translation services.